Neurosearch obtains permission to initiate trials of its new epilepsy drug  

The Danish biopharmaceutical company has obtained permission to initiate two phase II trials of its drug NS1209 for the treatment of epilepsy

The Danish biopharmaceutical company Neurosearch has obtained permission to initiate two phase II clinical trials of its new drug NS1209 for the treatment of epilepsy. The studies will be conducted in 60 patients at 10 clinical centres in Denmark, Sweden and Finland. The trials will evaluate whether NS1209 can be developed into a drug for the treatment of severe, long duration seizures.


In preclinical models NS1209 has stopped seizures more efficiently than currently known epilepsy drugs. Earlier trials also indicated that NS1209 can protect against brain damage and thereby improve patients' survival and life quality considerably.


About 20% of all epilepsy patients suffer from long duration seizures. The world market for epilepsy drugs was worth approximately DKK 36 billion (USD 6 billion) in 2001. The news is reported by Ritzau online.


Link > Neurosearch 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×